Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Peng Shen¹, Wenzhao Zhong²

Affiliations

¹ Department of Oncology, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
² Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

PMID: 29708118
PMCID: PMC5906233
DOI: 10.21037/jtd.2018.03.97

Editorial

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Peng Shen et al. J Thorac Dis. 2018 Mar.

. 2018 Mar;10(3):1364-1369.

doi: 10.21037/jtd.2018.03.97.

Authors

Peng Shen¹, Wenzhao Zhong²

Affiliations

¹ Department of Oncology, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
² Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

PMID: 29708118
PMCID: PMC5906233
DOI: 10.21037/jtd.2018.03.97

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

**Figure 1**
Evolution of adjuvant treatment diagram. NSCLC, non-small cell lung cancer; MRD, minimal residual disease; CT, chemotherapy; RT, radiotherapy; TT, targeted therapy.

See this image and copyright information in PMC

Comment on

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.

Cited by

Novel treatment strategies for early-stage lung cancer: the oncologist's perspective.
Indini A, Rijavec E, Bareggi C, Grossi F. Indini A, et al. J Thorac Dis. 2020 Jun;12(6):3390-3398. doi: 10.21037/jtd.2020.02.46. J Thorac Dis. 2020. PMID: 32642264 Free PMC article. Review.
Making adjuvant therapy decisions with uncertain data.
Gyawali B, Prasad V. Gyawali B, et al. Ann Oncol. 2019 Mar 1;30(3):361-364. doi: 10.1093/annonc/mdz039. Ann Oncol. 2019. PMID: 30715160 Free PMC article. No abstract available.
Genetic alteration profile of EGFR-mutant resected IIB-IIIA stage NSCLC and correlation to clinical outcomes.
Deng Q, Qiu Y, Jia J, Tang H, Liu L, Huang L, He D, Dong X, Yang H. Deng Q, et al. Transl Lung Cancer Res. 2019 Dec;8(6):838-846. doi: 10.21037/tlcr.2019.10.19. Transl Lung Cancer Res. 2019. PMID: 32010562 Free PMC article.
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.
Yang XN, Yan HH, Wang J, Chu XY, Liu ZD, Shen Y, Ma HT, Fu XN, Hu J, Zhou NK, Liu YY, Zhou XM, Li JS, Yang K, Li J, Xu L, Wang SY, Wang Q, Liu LX, Xu S, Chen ZY, Lou HH, Wang CL, Cheng Y, Liu SY, Zhang XC, Zhong WZ, Wu YL. Yang XN, et al. JTO Clin Res Rep. 2021 Nov 25;3(1):100257. doi: 10.1016/j.jtocrr.2021.100257. eCollection 2022 Jan. JTO Clin Res Rep. 2021. PMID: 34977823 Free PMC article.
Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study.
Zeng Z, Yan B, Chen Y, Zhang L, Zhu J, Yang F, Wei F, Tam TCC, Kauffmann-Guerrero D, Soo RA, Ren X, You J. Zeng Z, et al. Transl Lung Cancer Res. 2020 Dec;9(6):2401-2410. doi: 10.21037/tlcr-20-1214. Transl Lung Cancer Res. 2020. PMID: 33489802 Free PMC article.

References

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. 10.3322/caac.21338 - DOI - PubMed
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. 10.1002/ijc.29210 - DOI - PubMed
1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94. 10.1016/S0025-6196(11)60735-0 - DOI - PMC - PubMed
1. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014;25:1681-90. 10.1093/annonc/mdu145 - DOI - PubMed
1. NSCLC Meta-analyses Collaborative Group , Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77. 10.1016/S0140-6736(10)60059-1 - DOI - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Affiliations

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous